Menu
Subscribe to our Email Alerts
Home
About Us
Company Overview
Our Values
Board of Directors
Team
Scientific Advisers
Clinical Advisers
Corporate Directory
Corporate Governance
Pipeline
Pipeline
Cancer Program
Fibrosis Program
Clinical Trial
Investor Information
Welcome
Investor Fact Sheet
Investor Presentations
Media
Top 20 Shareholders
Shareholder Services
Investor FAQs
US Shareholders
Announcements and Reports
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
Contact Us
Contact Us
Email Alerts
Announcements and Reports
Home
>
Announcements and Reports
>
ASX Announcements
ASX Announcements
Publications
Annual Reports
Half Yearly Reports
Quarterly Reports
Research Reports
ASX Announcements
Filter by Year:
2023
2022
2021
2020
2019
2018
16-Dec-2021
Amplia Provides Updated Investor Presentation
15-Dec-2021
Update - Application for quotation of securities - ATX
14-Dec-2021
Update - Proposed issue of securities - ATX
10-Dec-2021
Entitlement Offer Completed
2-Dec-2021
Amplia Awarded $2.1M R&D Cash Flow Loan
24-Nov-2021
App 4D and Financial Report Half Year ended 30 Sep 2021
19-Nov-2021
Notice of Extraordinary General Meeting - 17 Dec 2021
18-Nov-2021
Summary Results - Successful Phase 1 Clinical Trial AMP945
17-Nov-2021
Inhibition of FAK by AMP945 in Phase 1 Clinical Trial
16-Nov-2021
Becoming a Substantial Holder - Acorn Capital Limited
Previous
1
2
3
4
5
6
7
8
9
Next
